This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wimmer, I. Articles by Burg, G. Search for Related Content PubMed PubMed Citation Articles by Wimmer, I. Articles by Burg, G.

Prognostic Value of Serum 5-S-Cysteinyldopa for Monitoring Human Metastatic Melanoma during Immunochemotherapy¹

Department of Dermatology, University Hospital, CH-8091 Zurich, Switzerland [I. W., J. C. M., R. D., A. F., G. B.], and Deparment of Biostatistics, Institute of Social and Preventive Medicine, University of Zurich, CH-8006 Zurich, Switzerland [B. S.]

The melanin metabolite 5-S-cysteinyldopa (5-S-CD) has been reported to be helpful in detecting occult melanoma metastases and as a prognostic marker in B16 melanoma-bearing mice. The goal of our study was to analyze the significance of the serum 5-S-CD level for the biochemical detection of metastases in human malignant melanoma (MM) and for monitoring the progression or the immunochemotherapeutically induced regression of MM.

From 11 patients with metastatic MM observed between 1991 and 1995, serum samples were collected before and after each cycle of immunotherapy or immunochemotherapy. Samples were analyzed for 5-S-CD by automated high performance liquid chromatography with electrochemical detection.

Cycles of immunochemotherapy consisted of human interleukin 2 and IFN- (four patients) or of human interleukin 2, IFN-, and dacarbazine (seven patients).

Serum value of 5-S-CD in our normal controls was 1.9 ± 0.6 ng/ml. All patients with metastatic MM showed 5-S-CD serum levels above the upper normal limit of 3.2 ng/ml (10 nM) and ranged from 2.3-fold (4.3 ± 3.9 ng/ml) of the normal control values in early stages of metastases to more than 50-fold (94.3 ± 220.3 ng/ml) of the normal control values in advanced stages of the disease. In 28 of 41 (68%) immunochemotherapeutical cycles, a decrease of 5-S-CD was seen during therapy, and in 13 cycles (31.7%), an increase was seen. Patients with more than 68% decreasing cycles (defined as responders; n = 5) showed significantly longer survival times (P = 0.008) than patients with less than 68% decreasing cycles (nonresponders; n = 6). High levels of 5-S-CD were also observed in metastasizing amelanotic melanoma.

Serum 5-S-CD is a useful marker for monitoring the clinical course of MM patients, for discriminating between responders and nonresponders to immunochemotherapy, and as a prognostic factor concerning survival time and death risk.

¹ Part of this work was presented as a poster at the 58th Meeting of the Society of Investigative Dermatology, April 23–27, in Washington, D.C., 1997.

² To whom requests for reprints should be addressed, at Department of Dermatology, University Hospital, CH-8091 Zurich, Switzerland.

Received 5/16/97. Accepted 9/19/97.

This article has been cited by other articles:

				K. Shikuma, M. Omasa, Y. Yutaka, M. Okuda, and T. Taki Treatment of Primary Melanoma of the Lung Monitored by 5-S-Cysteinyldopa Levels Ann. Thorac. Surg., April 1, 2009; 87(4): 1264 - 1266. [Abstract] [Full Text] [PDF]

				Y. Azuma, Y. Ishikawa, S. Kawai, T. Tsunenari, H. Tsunoda, T. Igawa, S.-i. Iida, M. Nanami, M. Suzuki, R. F. Irie, et al. Recombinant Human Hexamer-Dominant IgM Monoclonal Antibody to Ganglioside GM3 for Treatment of Melanoma Clin. Cancer Res., May 1, 2007; 13(9): 2745 - 2750. [Abstract] [Full Text] [PDF]

				Y. Ikuta, T. Nakatsura, T. Kageshita, S. Fukushima, S. Ito, K. Wakamatsu, H. Baba, and Y. Nishimura Highly Sensitive Detection of Melanoma at an Early Stage Based on the Increased Serum Secreted Protein Acidic and Rich in Cysteine and Glypican-3 Levels Clin. Cancer Res., November 15, 2005; 11(22): 8079 - 8088. [Abstract] [Full Text] [PDF]

				T. Nakatsura, T. Kageshita, S. Ito, K. Wakamatsu, M. Monji, Y. Ikuta, S. Senju, T. Ono, and Y. Nishimura Identification of Glypican-3 as a Novel Tumor Marker for Melanoma Clin. Cancer Res., October 1, 2004; 10(19): 6612 - 6621. [Abstract] [Full Text] [PDF]